PNC Financial Services Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-6,911
| Closed | -$1.19M | – | 4738 |
|
|
2021
Q3 | $1.19M | Sell |
6,911
-23
| -0.3% | -$3.01K | ﹤0.01% | 1113 |
|
|
2021
Q2 | $870K | Sell |
6,934
-587
| -8% | -$74K | ﹤0.01% | 1270 |
|
|
2021
Q1 | $1.02M | Sell |
7,521
-123
| -2% | -$15.9K | ﹤0.01% | 1148 |
|
|
2020
Q4 | $979K | Sell |
7,644
-196
| -3% | -$23K | ﹤0.01% | 1137 |
|
|
2020
Q3 | $882K | Buy |
7,840
+1,354
| +21% | +$135K | ﹤0.01% | 1094 |
|
|
2020
Q2 | $618K | Buy |
6,486
+355
| +6% | +$34.2K | ﹤0.01% | 1257 |
|
|
2020
Q1 | $551K | Sell |
6,131
-2,487
| -29% | -$193K | ﹤0.01% | 1242 |
|
|
2019
Q4 | $458K | Buy |
8,618
+732
| +9% | +$33.4K | ﹤0.01% | 1534 |
|
|
2019
Q3 | $313K | Buy |
7,886
+240
| +3% | +$10.4K | ﹤0.01% | 1871 |
|
|
2019
Q2 | $314K | Buy |
7,646
+366
| +5% | +$15.2K | ﹤0.01% | 1906 |
|
|
2019
Q1 | $339K | Sell |
7,280
-160
| -2% | -$7.03K | ﹤0.01% | 1844 |
|
|
2018
Q4 | $323K | Buy |
7,440
+1,460
| +24% | +$72.9K | ﹤0.01% | 1777 |
|
|
2018
Q3 | $343K | Buy |
5,980
+1,596
| +36% | +$78.4K | ﹤0.01% | 1882 |
|
|
2018
Q2 | $213K | Sell |
4,384
-126,735
| -97% | -$4.62M | ﹤0.01% | 2145 |
|
|
2018
Q1 | $5.13M | Buy |
131,119
+122,907
| +1,497% | +$5.22M | 0.01% | 724 |
|
|
2017
Q4 | $348K | Buy |
8,212
+132
| +2% | +$4.95K | ﹤0.01% | 1854 |
|
|
2017
Q3 | $302K | Sell |
8,080
-380
| -4% | -$13.2K | ﹤0.01% | 1911 |
|
|
2017
Q2 | $258K | Buy |
8,460
+3,100
| +58% | +$89.8K | ﹤0.01% | 1998 |
|
|
2017
Q1 | $142K | Sell |
5,360
-400
| -7% | -$10.5K | ﹤0.01% | 2299 |
|
|
2016
Q4 | $146K | Buy |
5,760
+740
| +15% | +$23.4K | ﹤0.01% | 2269 |
|
|
2016
Q3 | $182K | Sell |
5,020
-35
| -0.7% | -$1.16K | ﹤0.01% | 2141 |
|
|
2016
Q2 | $172K | Buy |
5,055
+4,935
| +4,113% | +$160K | ﹤0.01% | 2182 |
|
|
2016
Q1 | $3K | Buy |
120
+4
| +3% | +$116 | ﹤0.01% | 4100 |
|
|
2015
Q4 | $6K | Hold |
116
| – | – | ﹤0.01% | 3819 |
|
|
2015
Q3 | $3K | Buy |
116
+4
| +4% | +$120 | ﹤0.01% | 4192 |
|
|
2015
Q2 | $4K | Buy |
112
+51
| +84% | +$1.65K | ﹤0.01% | 4201 |
|
|
2015
Q1 | $2K | Buy |
+61
| New | +$2.43K | ﹤0.01% | 4344 |
|
PNC Financial Services Group's XLRN Position: Q4 2021 in Review
PNC Financial Services Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 6,911 shares — an estimated $1.19M sold.
PNC Financial Services Group first reported a position in XLRN in Q1 2015 and held it in 27 quarters. The position peaked at $5.13M in Q1 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- PNC Financial Services Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- PNC Financial Services Group sold 6,911 Acceleron Pharma shares in Q4 2021, an estimated $1.19M.
- PNC Financial Services Group first reported a position in Acceleron Pharma in Q1 2015 and held it in 27 quarters.
- PNC Financial Services Group's Acceleron Pharma position peaked at $5.13M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on PNC Financial Services Group's 13F filing for Q4 2021, filed 11 Feb 2022.